Your browser doesn't support javascript.
loading
Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma.
Mai, E K; Bertsch, U; Dürig, J; Kunz, C; Haenel, M; Blau, I W; Munder, M; Jauch, A; Schurich, B; Hielscher, T; Merz, M; Huegle-Doerr, B; Seckinger, A; Hose, D; Hillengass, J; Raab, M S; Neben, K; Lindemann, H-W; Zeis, M; Gerecke, C; Schmidt-Wolf, I G H; Weisel, K; Scheid, C; Salwender, H; Goldschmidt, H.
Afiliação
  • Mai EK; Department of Internal Medicine V, University Hospital Heidelberg and National Center for Tumor Diseases (NCT) Heidelberg on behalf of the German-Speaking Myeloma Multicenter Group (GMMG), Heidelberg, Germany.
  • Bertsch U; Department of Internal Medicine V, University Hospital Heidelberg and National Center for Tumor Diseases (NCT) Heidelberg on behalf of the German-Speaking Myeloma Multicenter Group (GMMG), Heidelberg, Germany.
  • Dürig J; Department of Hematology, University Hospital Essen, Essen, Germany.
  • Kunz C; Division of Biostatistics, German Cancer Research Center (DKFZ) Heidelberg, Heidelberg, Germany.
  • Haenel M; Department of Internal Medicine III, Klinikum Chemnitz, Chemnitz, Germany.
  • Blau IW; Medical Clinic, Charité University Medicine Berlin, Berlin, Germany.
  • Munder M; Department of Internal Medicine III, University Medical Center Mainz, Mainz, Germany.
  • Jauch A; Institute of Human Genetics, University of Heidelberg, Heidelberg, Germany.
  • Schurich B; Coordination Centers for Clinical Trials (KKS), University Hospital Heidelberg, Heidelberg, Germany.
  • Hielscher T; Division of Biostatistics, German Cancer Research Center (DKFZ) Heidelberg, Heidelberg, Germany.
  • Merz M; Department of Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany.
  • Huegle-Doerr B; Department of Internal Medicine V, University Hospital Heidelberg and National Center for Tumor Diseases (NCT) Heidelberg on behalf of the German-Speaking Myeloma Multicenter Group (GMMG), Heidelberg, Germany.
  • Seckinger A; Department of Internal Medicine V, University Hospital Heidelberg and National Center for Tumor Diseases (NCT) Heidelberg on behalf of the German-Speaking Myeloma Multicenter Group (GMMG), Heidelberg, Germany.
  • Hose D; Department of Internal Medicine V, University Hospital Heidelberg and National Center for Tumor Diseases (NCT) Heidelberg on behalf of the German-Speaking Myeloma Multicenter Group (GMMG), Heidelberg, Germany.
  • Hillengass J; Department of Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany.
  • Raab MS; Department of Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany.
  • Neben K; Department of Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany.
  • Lindemann HW; Department of Hematology and Oncology, Katholisches Krankenhaus Hagen, Hagen, Germany.
  • Zeis M; Department of Hematology, Asklepios Hospital St. Georg Hamburg, Hamburg, Germany.
  • Gerecke C; Department of Hematology and Oncology, Helios Hospital Berlin Buch, Berlin, Germany.
  • Schmidt-Wolf IG; Center for Integrated Oncology, University Hospital Bonn, Bonn, Germany.
  • Weisel K; Department of Hematology, Oncology and Immunology, University Hospital Tübingen, Tübingen, Germany.
  • Scheid C; Department of Internal Medicine I, University Hospital Köln, Köln, Germany.
  • Salwender H; Department of Hematology and Oncology, Asklepios Hospital Hamburg Altona, Hamburg, Germany.
  • Goldschmidt H; Department of Internal Medicine V, University Hospital Heidelberg and National Center for Tumor Diseases (NCT) Heidelberg on behalf of the German-Speaking Myeloma Multicenter Group (GMMG), Heidelberg, Germany.
Leukemia ; 29(8): 1721-9, 2015 Aug.
Article em En | MEDLINE | ID: mdl-25787915
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Mieloma Múltiplo Tipo de estudo: Clinical_trials / Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2015 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Mieloma Múltiplo Tipo de estudo: Clinical_trials / Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2015 Tipo de documento: Article